{"id":770889,"title":"Canada’s experience with the live-attenuated influenza vaccine: National Advisory Committee on Immunization responses to post-market vaccine monitoring signals, CCDR 47(5/6) - Canada.ca","sourceCode":"phac","sourceName":"Public Health Agency of Canada","language":"en","captureDate":"2026-03-06","captureTimestamp":"2026-03-06T03:47:56.494000+00:00","jobId":7,"originalUrl":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2021-47/issue-5-6-may-june-2021/national-advisory-committee-immunization-recommendations-post-market-vaccine-live-attenuated-influenza-vaccine.html","snippet":"NACI recommendations to post-market vaccine monitoring signals with the live-attenuated influenza vaccine Download this article as a PDF Published by: The Public Health Agency of Canada Issue: Volume 47-5/6: Responding to New Clusters of COVID-19 Date published: May/June 2021…","rawSnapshotUrl":"/api/snapshots/raw/770889","browseUrl":"https://replay.healtharchive.ca/job-7/20260306034756/https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2021-47/issue-5-6-may-june-2021/national-advisory-committee-immunization-recommendations-post-market-vaccine-live-attenuated-influenza-vaccine.html#ha_snapshot=770889","mimeType":"text/html","statusCode":200,"captureBackend":"playwright_warc","captureFidelity":"fallback"}